EVOGENIX, UNIVERSITY OF MASSACHUSETTS TO DEVELOP ANTICANCER ANTIBODY

A A

Evogenix has made an agreement with the University of Massachusetts Medical School (UMMS) to develop an anti-cancer antibody. Under the deal, Evogenix will apply its technologies to rapidly advance the hamster antibody DMF10, which has shown evidence of activity against lung cancer and melanoma.

Evogenix will use its technologies to advance DMF10 to the stage where it can be tested in patients and "humanized" to eliminate rejection and kill cancer. Before out-licensing the antibody, the company will spend the next 12 months trying to fast-track the development of the cancer treatment.